{"id":195851,"date":"2026-06-26T12:23:23","date_gmt":"2026-06-26T20:23:23","guid":{"rendered":"https:\/\/lukeford.net\/blog\/?p=195851"},"modified":"2026-06-26T17:28:36","modified_gmt":"2026-06-27T01:28:36","slug":"patrick-soon-shiong","status":"publish","type":"post","link":"https:\/\/lukeford.net\/blog\/?p=195851","title":{"rendered":"Patrick Soon-Shiong"},"content":{"rendered":"

Patrick Soon-Shiong<\/a> (b. 1952) is a surgeon, medical inventor, biotechnology executive, investor, philanthropist, and newspaper proprietor whose career joins academic medicine to pharmaceutical commerce on a scale few physicians have matched. He built a large private fortunes through the development and sale of injectable generics and the cancer drug Abraxane, and he has since redirected much of that capital toward an integrated biomedical enterprise spanning oncology, immunotherapy, genomics, artificial intelligence, and data science. Since 2018 he has also owned the Los Angeles Times<\/a>, a position that has made him one of the most consequential private holders of a major American newspaper at a moment when metropolitan journalism has contracted across the country. His record combines scientific ambition, commercial success, and recurring controversy over both his business claims and his stewardship of the press.<\/p>\n

He was born in Port Elizabeth, South Africa, on July 29, 1952, the child of Chinese immigrant parents of Hakka ancestry who had fled Japanese-occupied China during the Second World War. He came of age under apartheid, an experience he has credited with shaping a lasting attachment to medicine, scientific reasoning, and democratic institutions. He graduated from the medical school of the University of the Witwatersrand<\/a> at twenty-three, finishing near the top of his class, and completed an internship in Johannesburg. He then moved to Canada, where he earned a master’s degree in surgery from the University of British Columbia<\/a>, before immigrating to the United States for surgical training at the University of California, Los Angeles<\/a>. He became a board-certified transplant surgeon in 1984 and later a naturalized American citizen.<\/p>\n

Through the 1980s and into the early 1990s, Soon-Shiong established himself as an experimental transplant surgeon at UCLA. He performed the institution’s first whole-pancreas transplant and pursued procedures using pancreatic islet-cell transplantation for patients with Type 1 diabetes, work directed at restoring insulin production and improving the survival of grafted tissue. He held a successful academic post, yet he came to believe that many promising discoveries never reached patients because of weaknesses in the pharmaceutical industry. That conviction drew him out of the university and toward enterprise.<\/p>\n

His first large commercial success came through American Pharmaceutical Partners, a maker of injectable generic medicines that he built into a major supplier to hospitals. He sold the company to Fresenius SE<\/a> in 2008 for roughly $5.6 billion. A second and larger success followed through Abraxis BioScience, which brought to market Abraxane<\/a>, a nanoparticle formulation of paclitaxel designed to improve the delivery of the drug while reducing some of the toxicity associated with conventional chemotherapy. The Food and Drug Administration<\/a> approved Abraxane in 2005 for metastatic breast cancer, and the drug later gained approvals for pancreatic cancer and non-small cell lung cancer. It generated billions of dollars in revenue and ranks among the commercially successful oncology drugs of the early twenty-first century. In 2010 Soon-Shiong sold Abraxis to Celgene for close to $3 billion. Together with the earlier sale of American Pharmaceutical Partners, these transactions placed him among the wealthiest physicians who have ever lived.<\/p>\n

Rather than retire, he committed much of his fortune to building an integrated biomedical enterprise. He founded NantWorks, a network of companies devoted to cancer research, artificial intelligence, genomics, data science, diagnostics, immunotherapy, energy storage, advanced communications, and other emerging fields. His central idea holds that medicine should operate as a continuously learning system, one that draws genomic sequencing, clinical records, imaging, machine computation, and real-time patient monitoring into a single circuit that yields individualized treatment.<\/p>\n

Within that constellation, ImmunityBio<\/a> has become his flagship. The company develops immunotherapies meant to direct the body’s own immune system against cancer and infectious disease. In 2024 the FDA approved its drug Anktiva (nogapendekin alfa inbakicept-pmln) for certain patients with BCG-unresponsive non-muscle invasive bladder cancer, a milestone of his later career. The company has since sought expanded indications for bladder and lung cancer while advancing a broader platform built around natural killer cell therapies and related approaches.<\/p>\n

His scientific philosophy departs from conventional pharmaceutical development. He treats cancer less as a set of isolated diseases than as a systems problem that calls for the simultaneous integration of genetics, immunology, computing, artificial intelligence, and large-scale data analysis. He has promoted precision medicine throughout his career, arguing that each patient’s tumor carries distinct biological features that demand individualized therapy rather than standardized protocols.<\/p>\n

His later scientific work has also drawn regulatory scrutiny. In 2026 the FDA issued a warning letter over promotional statements about Anktiva that regulators judged to overstate the drug’s approved uses and to imply broader cancer benefits that the evidence had not established. The episode reflects a recurring tension across his career between an expansive vision for new therapies and the cautious standards that regulators impose.<\/p>\n

Beyond medicine, Soon-Shiong has invested in education, philanthropy, and civic life. Through the Chan Soon-Shiong Family Foundation, which he chairs with his wife Michele Chan, he has given hundreds of millions of dollars to scientific research, healthcare, education, and community development. The foundation has supported hospitals, universities, biomedical institutes, and educational projects in both the United States and South Africa. He has kept long-standing academic appointments at UCLA and has collaborated with researchers at numerous universities.<\/p>\n

He entered professional sports ownership in 2010 by buying a minority stake in the Los Angeles Lakers<\/a>. He has held it as a largely passive investor, though the stake reinforced his standing in the civic and business circles of the city.<\/p>\n

His public profile widened in 2018 when he bought the Los Angeles Times and the San Diego Union-Tribune<\/a> from Tronc for nearly $500 million, assuming substantial pension obligations in the bargain. The purchase ended years of corporate instability and drew early optimism from journalists, civic leaders, and readers who hoped local ownership might restore one of the country’s great metropolitan papers. He appointed experienced editors, expanded hiring in the first years, and promised to modernize the paper through technology. He later sold the San Diego Union-Tribune and kept the Los Angeles Times as his principal media holding.<\/p>\n

His stewardship has proved harder than his opening vision suggested. The paper has continued to struggle against falling advertising revenue, the demands of digital transition, and the financial pressures that weigh on metropolitan journalism everywhere. Rounds of layoffs, executive departures, and editorial disputes have brought criticism from staff and outside observers. Soon-Shiong has taken a growing personal interest in editorial policy, arguing that newspapers should reduce ideological polarization and rebuild public trust by carrying a wider range of viewpoints. His decision to block the editorial board from endorsing a presidential candidate in 2024 prompted resignations and public controversy, and it sharpened a longer debate over the proper reach of an owner into the newsroom.<\/p>\n

His role in public health widened during the COVID-19 pandemic. Through his companies he pursued vaccine work aimed at stimulating T-cell immunity alongside antibody responses, and he argued for expanded vaccine manufacturing in South Africa to narrow global inequalities in access to advanced medicine.<\/p>\n

He has continued to pursue an ambitious long-term plan for the paper. In 2025 he announced an intention to take Los Angeles Times Media Group<\/a> public through a mix of private financing and a future offering. The proposed holding company would join the newspaper to LA Times Studios, NantGames, and related media and technology assets, diversifying revenue beyond journalism alone. The early plan envisioned a New York Stock Exchange listing in 2026, though by early 2026 he acknowledged that the timetable had grown uncertain and might extend into 2027. He has said repeatedly that he does not intend to sell the paper, and that he hopes instead to establish an ownership model capable of preserving independent journalism while attracting long-term investment. As executive chairman of both ImmunityBio and Los Angeles Times Media Group, he divides his attention between biotechnology and media while promoting connections among biomedical research, artificial intelligence, advanced computing, and financial technology as parts of a single innovation enterprise.<\/p>\n

Soon-Shiong has never settled into a conventional political category. He describes himself as independent and frames his public interventions in the language of scientific reasoning, public health, institutional reform, and technological innovation rather than party. His readiness to challenge prevailing orthodoxies, in medicine and in journalism alike, has earned him admiration from some observers and sharp criticism from others.<\/p>\n

His business record has invited skepticism as well as praise. Several ventures inside the NantWorks network have drawn investor doubt over commercialization timelines and ambitious technological claims. Critics ask whether some of his companies promised more than they delivered, while supporters answer that long-term biomedical innovation requires patience and unusually large capital. His management of the Los Angeles Times has likewise drawn criticism over finances, staffing cuts, editorial intervention, and newsroom instability, even as supporters credit him with keeping one of the country’s important newspapers under independent local ownership during a period when many dailies have closed or vanished into national chains.<\/p>\n

His influence rests on an uncommon combination of roles. He has held distinction as a practicing surgeon, a medical inventor, a biotechnology executive, a billionaire investor, a philanthropist, a sports owner, and a newspaper proprietor. Few modern business figures have exercised comparable reach across medicine, science, technology, media, and civic life. Whether one regards him chiefly as an inventive physician, an ambitious entrepreneur, or a contested media owner, Patrick Soon-Shiong stands among the defining figures of contemporary American biotechnology and among the most consequential private owners of a major American newspaper.<\/p>\n

Curing Death: Patrick Soon-Shiong and the Hero System<\/strong><\/p>\n

The pancreas arrives at the table in a basin of cold saline. The scrub nurse lifts it with both hands and the resident leans in to see. It does not look like much, a soft gray-pink organ, smaller than the lay imagination expects, slick and faintly translucent at the edges. The patient on the table has Type 1 diabetes and a failing kidney and a number on his chart that the anesthesiologist watches more than he watches the man. Patrick Soon-Shiong (b. 1952) takes the organ in his gloved hands. He has the gown, the loupes, the particular stillness that surgeons cultivate and laymen mistake for calm. For the next hour he reroutes a man’s mortality. He clamps, he sews, he releases the clamp and watches the tissue pink up as blood finds the new vessels. When it holds, the room exhales. A man who an hour ago carried a death sentence in his blood sugar now carries a borrowed organ and a few more years.<\/p>\n

This is where the hero system begins, in the hands.<\/p>\n

Ernest Becker<\/a> (1924-1974) built his account of human striving on a single terror. In The Denial of Death<\/a> (1973) he argued that man knows he will die and cannot bear the knowledge, and so he builds. He builds a self, a name, a body of work, a fortune, a faith, a cathedral, a nation, anything that promises to outlast the body and to confer the feeling of cosmic significance that the rotting animal cannot supply on its own. Becker called the scheme a hero system. Each culture hands its members a script for heroism, a way to earn the sense that one counts in the order of things and will leave a mark that death cannot erase. In Escape from Evil (1975) he added the darker corollary. Hero systems collide. What one man counts as the highest good, another reads as profanation, and men kill each other in the name of life. The trouble is not that some men lack a hero system. The trouble is that there are many, and each looks like idolatry from inside a rival one.<\/p>\n

Soon-Shiong has a hero system, and at its center sits a word.<\/p>\n

The word is cure.<\/p>\n

Listen to how he uses it. Cancer should yield to a continuously learning system, he says, one that gathers a patient’s genome, his scans, his records, his immune profile, and feeds them all into a single engine that learns from every case and returns an answer fitted to the one tumor in front of it. He treats cancer less as a set of separate diseases than as a problem in computation and immunology waiting for enough data and enough capital. He spent a fortune building toward it. He spent it on the natural killer cell platform at ImmunityBio, on the genomic and imaging companies inside NantWorks, on a vision of medicine that corrects itself the way a good model corrects itself, run after run, toward the answer. To him the word cure names a destination that careful men reach if they refuse to quit before the data arrive.<\/p>\n

Now watch the same word travel.<\/p>\n

The bench immunologist will not say it. She is forty, she keeps a thermos of cold coffee by the cell incubator, and she has a freezer full of vials that represent eleven years of her life. When a reporter asks whether her therapy cures the disease she corrects him before he finishes the sentence. Durable complete response, she says. We say durable complete response. Cure is a word for press releases. Inside her hero system the heroism lies in the discipline of not overclaiming, in the paper that survives replication, in the citation that other careful people will still trust in twenty years. To say cure is to spend authority she has not earned. The sin is small and it is real. Her immortality is the work that stands, and the work stands only if she guards the words.<\/p>\n

The pediatric oncology nurse hears the word at three in the morning. A mother has not slept in four days and she takes the nurse’s wrist in the hallway and asks, in the flat voice of the truly frightened, whether her son will be cured. The nurse has watched the word do harm. She has watched it raise a family and then break it. In her hero system the heroism is presence, the hand on the shoulder, the willingness to stay in the room when the machines start their alarms and the residents find reasons to be elsewhere. Death is not her enemy to be defeated. Death is the event she attends. She has made her peace with attending it well, and a man who promises to abolish it strikes her as a man who has never stood in that hallway at three in the morning.<\/p>\n

In a storefront church off a boulevard with a check-cashing place on one side and a tax preparer on the other, a Pentecostal pastor lays hands on a woman with a tumor in her breast and the congregation calls out and the woman weeps. He believes the cure comes from Him. The body is not the self. Medicine is permitted, the pastor tells his people, the doctors do God’s work with their hands, but the source is not the needle. His hero system runs past death and out the other side, to a resurrection that no scan can confirm and no scan can refute. To him a man who locates salvation in a learning machine has mistaken the instrument for the hand that guides it. The error is not medical. The error is theological, and from where the pastor stands it is the oldest error there is, the worship of the made thing.<\/p>\n

The palliative physician has built her whole vocation on the refusal of the word. She runs a hospice. Her heroism inverts the surgeon’s at every point. She measures her work by the death that arrives without panic, the pain controlled, the family gathered, the old man who dies in his own bed having said what he needed to say. There is no cure here and she does not pretend there is one, and she has come to regard the promise of cure as a cruelty visited on the dying by people who cannot sit with them. When a patient arrives from an oncology service still chasing a fourth-line therapy, still enrolled in a trial, still being told by hopeful men that the next thing might work, she sees a person robbed of the chance to prepare. Her sacred good is the good death. His sacred word, in her ward, reads as the thing that steals it.<\/p>\n

A different room, glass and gray carpet, a view of low hills. The venture man wears the vest and keeps the term sheet face down on the table out of habit. He likes Soon-Shiong. He admires the ambition and he has put money behind it. But when the word cure comes up in a partners’ meeting somebody always says the quiet thing, which is that a cure is a single sale and a chronic therapy is an annuity. The math is not hidden and it is not evil to the man who says it. It is the grammar of his hero system, the fund’s vintage, the multiple, the letter to limited partners at the end of the year. He does not want patients to suffer. He wants returns, and he has trained himself not to confuse the two, and the training is the discipline he is proud of. In his world the word cure names a worse business than the disease, and the man who chases it is either a saint or a poor allocator of capital, and the venture man has not decided which.<\/p>\n

On a fixed income with a vial of insulin he is rationing toward the end of the month, a man hears cure on the radio and turns it off. He is not against the word. He is against its price. A cure that costs two hundred thousand dollars a year is a rumor to him, a thing that happens to other people in other tax brackets. His hero system, if you can call it that, runs on getting through, on not being a burden, on the dignity of paying his own way until he no longer can. Access is his sacred term and the activist who fights the drug companies on his behalf has built a whole life of heroism around it, around the fight against the price of the thing the surgeon wants to invent. To them the cure is not the end of the story. The cure is the beginning of an argument about who may have it.<\/p>\n

Across an ocean, in a health ministry in Gauteng, a deputy director-general reads about a South African-born billionaire who wants to build vaccine capacity on the continent so that the next time the world will not have to wait for the North to share. To her the words cure and vaccine carry a charge the surgeon may not fully feel. They mean sovereignty. They mean an end to the line at the back of the queue. Her hero system is national and it is shaped by a memory of waiting, of watching richer countries inoculate their citizens while hers buried theirs. She does not care whether the science is elegant. She cares whether the plant gets built and who owns it and whether the promise survives the news cycle that announced it.<\/p>\n

One word. Seven rooms. In each room the word makes sense, and in each room it makes a different sense, and the sense it makes is set by the hero system that contains it. Becker’s claim sits underneath all of this. There is no neutral cure that floats free of the systems that prize it. The immunologist’s caution, the nurse’s presence, the pastor’s resurrection, the palliativist’s good death, the investor’s annuity, the rationing man’s access, the official’s sovereignty, each is a way of standing against death or of standing with it, and each assigns the word its weight. The man who carries only one of these meanings, and carries it with the certainty of a surgeon who has held a working pancreas in his hands, will keep walking into rooms where his sacred word lands as someone else’s blasphemy.<\/p>\n

Becker would add a second observation about the fuel. In Escape from Evil he called money the modern immortality vehicle, congealed power over life, the purest form of the thing because it converts into any other and never dies on its own. Soon-Shiong is among the richest physicians who have ever lived, and the conventional reading says the money is the point and the cure is the cover story. Becker inverts it. The cure is the immortality project. The money is its sacred fuel. The man sold American Pharmaceutical Partners for billions and Abraxis for billions more, and he did not stop, because the fortune was never the destination. The fortune buys more runs of the experiment that defeats death. A man who has held mortality off for an hour with his hands wants to hold it off for a population, and then for a species, and the only instrument large enough is capital. The 2026 warning letter from the regulators, the charge that he oversold what the drug had shown, reads in the press as a marketing problem. Becker reads it as a believer running ahead of his evidence because the thing he believes in is not a drug. It is the abolition of the dragon, and a man who has seen the dragon up close finds the careful pace of the careful people hard to bear.<\/p>\n

Then he bought a newspaper, and the second hero system swallowed him.<\/p>\n

The Los Angeles Times has a sacred word of its own, and the word is not cure. The word is independence, and behind it stands a second word, trust, and behind both stands a structure the trade calls the wall. The wall separates the man who owns the paper from the words the paper prints. To a career journalist the wall is not a convenience. It is the thing that makes the work heroic, the reason the byline means anything, the promise that what you read was not bought. The journalist earns his immortality in the story that holds up, the one that named the powerful man and survived the lawsuit, the clip that his grandchildren will find. He guards the wall the way the immunologist guards her words, because the wall is where his significance lives.<\/p>\n

In the autumn of 2024 the owner stopped the editorial board from endorsing a candidate for president. He framed it in the language of his own hero system. Newspapers had grown partisan, he believed, and partisanship had cost them the public’s trust, and a paper that learned to carry more viewpoints might correct itself the way a good system corrects itself and earn the trust back. To him the decision served independence, freedom from the capture he saw in the trade. He used the word independence and he meant it.<\/p>\n

The newsroom heard the same word and understood the opposite. Editors resigned. Staff signed letters. To them independence meant the wall, and the owner had reached over the wall and pulled a page, and the reach was the profanation, whatever he called it. He thought he was defending the sacred thing. They thought he had desecrated it. Both used the word. Neither was lying. This is what Becker promised. Two hero systems, one vocabulary, and a collision that no amount of explanation can resolve, because the disagreement is not about facts. It is about what counts as heroism, and there is no court above the two systems to settle which one is right.<\/p>\n

He arrived in journalism fluent in one immortality language and certain it was the only one. He spoke of systems that learn and trust that can be engineered and balance that can be measured, the grammar of a man who cured what he could reach by gathering enough data and refusing to quit. In the newsroom that grammar reads as the destruction of the very thing he says he wants to save. You cannot engineer trust the way you titrate a dose. The journalists believe trust grows from the wall, and the wall is the thing he keeps reaching over, and so the harder he works to restore the trust the more of it he spends.<\/p>\n

He says he will not sell the paper. He says he wants to build an ownership model that outlasts him, a holding company, a public listing, a structure that keeps independent journalism alive after the founder is gone. Strip the business language and Becker is standing right there. The man wants the institution to survive him. He wanted the cure to survive him and the company to survive him and now he wants the paper to survive him, because the body will not, and a man who has spent his life holding off the one ending wants something with his hand on it still standing when his hand is gone.<\/p>\n

He began with a pancreas in a basin, an organ he could lift and place and watch turn pink with borrowed blood. Forty years later he is trying to do to death what he once did to a single failing organ, to clamp it, reroute it, hold it off for a population the way he held it off for a man on a table. The fortune is the instrument. The cure is the faith. The newspaper is the monument he did not invent and cannot fully control, which may be why he wants it, because the things a man builds himself die with his certainty, and the things he merely keeps alive might carry his name a little further into the dark.<\/p>\n

The word cure means a destination to him. It will go on meaning caution to the immunologist, presence to the nurse, the wrong business to the investor, a price to the rationing man, God to the pastor, a good death’s enemy to the palliativist, and sovereignty to the official in Gauteng. He cannot make them mean what he means. No one can. That is the condition Becker described, and the surgeon who has spent a life trying to defeat death is living it without quite seeing it, room by room, word by word, reaching over one wall after another in the sincere belief that everyone on the other side wants the same thing he does.<\/p>\n

The Exchange Rate: Patrick Soon-Shiong and the Journalistic Field<\/strong><\/p>\n

The boardroom at the Nant campus runs on his clock. The screens carry the genomic pipelines and the trial enrollments and the quarterly burn, and when Patrick Soon-Shiong (b. 1952) speaks the room arranges itself around the speaking. A deal lawyer in an open collar slides a term sheet across the table and waits. A young chief of staff has the next slide ready before the founder asks for it. In this room his word converts into action at par, dollar for dollar, because the room is built from his money and his money is the law of the place. He has spent four decades learning the feel of this game, the sense of when to press and when to wait, the body language of the man whom others have decided to please. He is fluent here. The fluency looks like nature.<\/p>\n

Twenty miles away, in a newsroom he also owns, the same man’s word does not convert.<\/p>\n

Pierre Bourdieu<\/a> (1930-2002) spent his life mapping spaces like these and the traffic between them. He called each space a field, a structured arena with its own stakes, its own rules, its own currency. Players enter a field already carrying capital, and Bourdieu counted several kinds. Economic capital is money and what money holds. Cultural capital is the schooling, the taste, the credential, the embodied ease that the schooled carry in their posture. Social capital is the network, the people who take your call. Symbolic capital is the recognition the others grant you, the prestige that a field confers and that no one can simply seize. The genius of the account lies in a single observation. Each kind of capital converts into the others, but the conversion runs through an exchange rate, and the rate is set by the field, and economic capital, the hardest and most liquid of the kinds, does not buy the same thing in every field. At the door of the journalistic field the tariff on money runs high, and the field demands payment in a coin the buyer does not hold.<\/p>\n

Trace his trajectory and the conversions stand out one by one.<\/p>\n

He began in the scientific field. Witwatersrand at twenty-three, near the top of the class, then surgery in Vancouver, then UCLA, then the first whole-pancreas transplant the institution had seen. Bourdieu would name what the young surgeon accumulated there, scientific capital, the recognition of peers who could judge the work, the slow consecration that the autonomous pole of science reserves for those who satisfy other scientists rather than the market. Abraxane carried that capital to its height. A nanoparticle formulation that the field’s own gatekeepers, the journals and the regulators, agreed had advanced the treatment of metastatic disease. He held real authority and he had earned it inside the field that grants it.<\/p>\n

Then he converted. American Pharmaceutical Partners to Fresenius for billions. Abraxis to Celgene for billions more. Scientific capital became economic capital at a favorable rate, because the two fields sit close and the bridges between them are well traveled. The conversion placed him among the richest physicians who have ever lived, and it placed him in what Bourdieu called the field of power, the high ground where the holders of the different capitals contend over which kind shall rule. In that field economic capital speaks loud. It builds the Nant campus and buys the stake in the basketball team and opens the doors that open for the very rich.<\/p>\n

Money is sovereign in the field of power. It is not sovereign inside every field that the field of power contains. This is the error that organizes the rest of the story.<\/p>\n

In 2018 he bought the Los Angeles Times and the San Diego Union-Tribune for nearly five hundred million dollars and took on the pension burden besides. He bought the building, the masthead, the archive, the presses, the badge on the lanyard. Bourdieu had a term for that holding. Objectified cultural capital, the institution in its physical and titular form, the thing you can deed and sell. He acquired all of it. What he could not acquire by purchase was the field’s specific capital, the journalistic kind, the byline that means something because peers respect it, the scoop, the story that named a powerful man and survived the suit, the recognition that one reporter grants another and that no proprietor can issue. That capital lives in the players, not in the property, and it answers to the field’s own law.<\/p>\n

The field’s law has a name the trade uses without irony. They call it the wall. The wall separates the man who owns the paper from the words the paper prints, and to the journalist the wall is not a courtesy. It is the nomos, the founding rule that makes the game worth playing. Bourdieu called the players’ shared investment in their game illusio, the deep belief that the stakes are real and the rules sacred, the belief without which no field could hold its players to the table. The journalist’s illusio is independence. His whole sense of his own worth rests on the conviction that what he wrote was not bought. Take the wall away and you have not changed the rules of his game. You have told him the game was never real.<\/p>\n

He arrived carrying the wrong illusio. His belief was the entrepreneur’s, the cure, the platform, the system that learns and corrects, the conviction that a proprietor sets direction the way a founder sets a company’s strategy. In the corporate field that belief holds and serves him. He carried it across the line into a field with a different law and did not feel the line under his feet, because the feel for one game does not transfer to another. Bourdieu called the feel the habitus, the set of dispositions a man acquires by playing, the second nature that tells him without thinking where the ball will go. Soon-Shiong has the habitus of the surgeon and the dealmaker, deep and reliable inside the fields that grew it. In the newsroom it misfires. He reads ownership as command because in every field he has mastered ownership is command.<\/p>\n

For a while the field extended him credit. When he bought the paper the journalists and the civic men greeted him with hope, and Bourdieu would read that hope precisely. The field offered provisional symbolic capital, a line of recognition advanced against future conduct, the civic savior who rescued a great paper from the chains that had nearly killed it. He hired editors. He expanded the staff. The credit looked sound. But symbolic capital is not a thing the field hands over and forgets. It is recognition, renewed or withdrawn by the agents who grant it, and it answers to whether the holder honors the field’s law.<\/p>\n

In the autumn of 2024 he stopped the editorial board from endorsing a candidate for president, and the line of credit closed.<\/p>\n

He explained the decision in the currency of his own field. Newspapers had grown partisan, he held, and partisanship had cost them the public’s trust, and a paper that carried more viewpoints might earn the trust back the way a good system earns back its accuracy, run by run. He used the word independence and meant freedom from the partisan capture he saw in the trade. The newsroom heard the same word and understood its opposite. To them independence meant the wall, and the owner had reached over the wall and pulled a page, and the reach was the violation whatever name he gave it. Editors resigned. Staff signed letters. Bourdieu would not call this a misunderstanding to be cleared up with a better memo. He would call it symbolic violence from the heteronomous pole, the intrusion of economic power into a field that defines its autonomy against precisely that power, and he would call the resignations the field policing its own boundary, the players paying in their own capital to defend the law that gives their capital value.<\/p>\n

The owner thought he was defending independence. The field thought he had desecrated it. Both used the word. The word did not convert.<\/p>\n

There is a harder turn in Bourdieu’s account, and the story rewards it. The journalistic field is among the least autonomous of the fields of cultural production. In On Television and Journalism (1996) he argued that the trade lives under the thumb of the market, that audience numbers and commercial pressure bend it daily, that its independence is thin and getting thinner. The journalists who rose against the owner were defending an autonomy the field holds only in part. He is the market made flesh, the proprietor, the very force the field has been losing ground to for thirty years, and they met him with the heat of people guarding a thing they fear is already slipping from their hands. The fierceness of the defense tracks the weakness of the wall. A field secure in its autonomy might absorb an owner’s whim. A field that feels the market closing in treats the owner’s whim as the thing itself arriving at the gate.<\/p>\n

The scientific field has its own boundary patrol, and it reached him too. In 2026 the regulators sent a warning letter over the promotion of his immunotherapy, the charge that the marketing claimed more than the evidence had shown. In the press the letter reads as a compliance matter. Bourdieu reads it as the field policing the conversion rate. Scientific capital earns its weight from the slow, peer-judged accumulation that the autonomous pole demands, and a man who converts it into promotional and economic capital faster than the field allows has tried to spend at a rate the field will not honor. The warning letter is the rate enforced. It says, in the dry voice of the regulator, that the coin minted at the bench does not buy unlimited claims in the market, and that the field that minted it retains the right to set its value.<\/p>\n

He says he will not sell the paper. He talks of a holding company, a public listing, a structure that joins the newsroom to studios and games and technology and carries independent journalism into a future that outlasts him. The plan is the entrepreneur’s answer to the field’s resistance, the move of a man who solves a problem by building a larger system around it. Bourdieu would point to what the plan reveals. The man keeps trying to convert his strongest capital, the economic, into the one capital it will not buy, the field’s recognition, and he keeps building bigger engines for the conversion, and the field keeps setting the rate against him. He owns the masthead and cannot own the byline. He owns the building and cannot own the wall. He holds the title to the institution and the institution’s symbolic capital lives in the people who keep resigning.<\/p>\n

The room at the Nant campus still runs on his clock. There his money is the law and his word converts at par. He came to journalism fluent in the conversion that built his life, the turning of one capital into another, and he met a field that taxes that conversion at a rate no fortune can pay, because the thing he wants from it is the field’s regard, and regard is the one holding the rich cannot purchase. He can buy the paper. He cannot buy the standing of a man whom the other players agree to honor. That standing is issued in a currency he does not hold, by a field that guards the right to issue it, and the harder he presses his own coin across the counter the more plainly the field reminds him that here, at this window, it does not convert.<\/p>\n

Alliance Theory<\/a><\/strong><\/p>\n

Patrick Soon-Shiong claims he wants to eliminate partisan bias from the media market. He frames his decisions to halt newspaper endorsements and expand content platforms as an effort to speak for all Americans. Alliance Theory treats this language of non-partisan balance as a strategic narrative rather than an expression of deep philosophical principles. Elites do not act out of pure intellectual consistency. Soon-Shiong uses the rhetoric of direct democracy to manage complex institutional pressures and shield his diverse corporate investments. <\/p>\n

Human psychology handles conflict by deploying specific reputation tools. When federal regulators penalize his biotechnology firms for misleading drug advertisements, his corporate network relies on coalitional logic. By appearing on media platforms that openly challenge government agencies, his allies portray his enterprise as a victim of institutional overreach. This narrative serves an outward-facing purpose. It seeks to gather third-party support from groups that already distrust established authority figures. The moral arguments about curing cancer operate as post-hoc justifications to protect his corporate standing. <\/p>\n

Soon-Shiong builds networks that span healthcare, artificial intelligence, and major news operations. These partnerships form through proximity, shared commercial benefit, and calculated alignment rather than permanent values. He moves between different political factions to maximize his reach. His actions show that elite belief systems remain highly flexible toolkits. They change to preserve status and maintain cooperation with useful allies across unstable cultural landscapes. <\/p>\n

The Great Delusion<\/em><\/a><\/strong><\/p>\n

In his 2018 book, The Great Delusion: Liberal Dreams and International Realities<\/em><\/a>, John J. Mearsheimer wrote:<\/p>\n

\nMy view is that we are profoundly social beings from the start to the finish of our lives and that individualism is of secondary importance… Liberalism downplays the social nature of human beings to the point of almost ignoring it, instead treating people largely as atomistic actors… Political liberalism… is an ideology that is individualistic at its core and assigns great importance to the concept of inalienable rights. This concern for rights is the basis of its universalism\u2014everyone on the planet has the same inherent set of rights\u2014and this is what motivates liberal states to pursue ambitious foreign policies. The public and scholarly discourse about liberalism since World War II has placed enormous emphasis on what are commonly called human rights. This is true all around the world, not just in the West. \u201cHuman rights,\u201d Samuel Moyn notes, \u201chave come to define the most elevated aspirations of both social movements and political entities\u2014state and interstate. They evoke hope and provoke action.\u201d
\n[Humans] do not operate as lone wolves but are born into social groups or societies that shape their identities well before they can assert their individualism. Moreover, individuals usually develop strong attachments to their group and are sometimes willing to make great sacrifices for their fellow members. Humans are often said to be tribal at their core. The main reason for our social nature is that the best way for a person to survive is to be embedded in a society and to cooperate with fellow members rather than act alone… Despite its elevated ranking, reason is the least important of the three ways we determine our preferences. It certainly is less important than socialization. The main reason socialization matters so much is that humans have a long childhood in which they are protected and nurtured by their families and the surrounding society, and meanwhile exposed to intense socialization. At the same time, they are only beginning to develop their critical faculties, so they are not equipped to think for themselves. By the time an individual reaches the point where his reasoning skills are well developed, his family and society have already imposed an enormous value infusion on him. Moreover, that individual is born with innate sentiments that also strongly influence how he thinks about the world around him. All of this means that people have limited choice in formulating a moral code, because so much of their thinking about right and wrong comes from inborn attitudes and socialization…\n<\/p><\/blockquote>\n

Mainstream media accounts treat Soon-Shiong through the lens of liberal individualism. They profile him as a brilliant, eccentric visionary who uses private capital to conquer cancer, revolutionize medical technology, and preserve civic journalism. Mearsheimer’s realism cuts through this celebratory framing. It reinterprets his career as a series of calculated adaptations designed to maximize material power, manage reputation, and capture critical infrastructure within an anarchic market.
\nSoon-Shiong bought the Los Angeles Times in 2018 for five hundred million dollars. He framed the purchase as a philanthropic intervention to save a civic institution and protect a free press, which liberal theory views as a pillar of democracy.
\nIf Mearsheimer is right, a major media company does not operate as a neutral public trust. It functions as an ideological standard used to defend a position within an elite coalition. In the competitive arena of American corporate life, a billionaire faces constant threats to his status and assets from rival coalitions, regulatory bodies, and public investigations. Owning a metropolitan newspaper gives Soon-Shiong an information asset. This asset allows him to manage his reputation, signal influence, and deter hostile moves by local or national political factions. The purchase was not an escape from tribal logic. It was the acquisition of an engine of influence to protect his broader corporate empire from structural vulnerability.
\nSoon-Shiong built his fortune on medical breakthroughs, notably the cancer drug Abraxane, and he frequently touts his vision for data-driven healthcare networks. He presents scientific reason and technological innovation as autonomous forces that can transcend political divisions and improve human life.
\nMearsheimer’s hierarchy of human preferences places independent reason and technical text last among human motivations, far behind the unreflective survival instincts of the group. The biopharmaceutical complex is not a disinterested scientific seminar. It is a highly competitive system where corporations, universities, and state agencies struggle over scarce resources, patent monopolies, and regulatory dominance. Soon-Shiong succeeds because he navigates this terrain as a realist. He builds alliances, secures state contracts, and aggressive shields his intellectual property from competitors. His scientific rhetoric serves as a tool to mobilize capital and manage public perception, while his actual power rests on hard material advantages and legal enforcement.
\nThrough his family foundation, Soon-Shiong directs massive investments into global health initiatives, medical research, and community development. He uses the universalist language of humanitarianism, suggesting that wealth can be deployed to dissolve traditional boundaries and cure systemic social ills.
\nMearsheimer’s realism reveals that this philanthropic framework is an ideological luxury product. The ability to fund global humanitarian causes depends entirely on the material power and baseline protection secured by a dominant state vehicle. Human beings remain tribal animals who rely on their immediate group for security under conditions of structural scarcity. Soon-Shiong’s foundations do not operate outside the logic of group competition. They serve as sophisticated tools to optimize his position within the domestic elite, reward loyal institutional partners, and project influence into foreign territories. When a systemic crisis occurs, these philanthropic networks fracture, and capital returns to the baseline task of securing the core assets of the primary group.<\/p>\n

‘A Big Misunderstanding’<\/a><\/strong><\/p>\n

Patrick Soon-Shiong is a fascinating test case for David Pinsof\u2019s thesis because his career bridges two heavily moralized fields: multi-billion-dollar biotech innovation and the ownership of major legacy media. As a transplant surgeon, the inventor of the cancer drug Abraxane, and the owner of the Los Angeles Times, Soon-Shiong operates with a massive public narrative of humanitarianism, scientific salvation, and civic service.
\nIf Pinsof is right, Soon-Shiong\u2019s career illustrates how an elite actor uses the misunderstanding myth in science and journalism to maximize status, shield business interests, and manage his position at the apex of the social hierarchy.
\nSoon-Shiong frequently frames his biotech research, particularly with his company ImmunityBio and the drug Anktiva, as a grand quest to unlock the body’s natural killer (NK) cells to “cure” or “prevent” cancer entirely. When regulators or traditional medical protocols slow down his timeline, he frames the friction as a institutional misunderstanding\u2014a failure of backward, bureaucratic agencies to comprehend a revolutionary scientific paradigm shift.
\nPinsof might say that medicine and drug approval are not pure exercises in logic and public health; they are highly competitive struggles for market share, patent control, and capital allocation.
\nSoon-Shiong\u2019s framing of his therapies as a universal “cancer vaccine” serves a distinct coalitional function. It allows him to bypass standard corporate skepticism and appeal directly to the public and investors as a lone visionary fighting a short-sighted system.
\nPinsof\u2019s logic was validated when federal regulators stepped in to warn that his public podcast claims overreaching the drug’s approved scope were misleading. The conflict is not an intellectual misunderstanding between a genius and a slow bureaucracy; it is a raw turf war where the state uses its regulatory apparatus to discipline a high-status player who attempts to rewrite the marketing rules for his own commercial gain.
\nWhen Soon-Shiong purchased the Los Angeles Times, he framed the acquisition as a philanthropic intervention to save a vital democratic institution from financial ruin and partisan bias. He frequently talks about “democratizing” the paper\u2014even announcing plans to take the parent company public to hand ownership back to “the people.” He frames polarization as a simple communication failure that an objective, independent newsroom can fix.
\nPinsof might say that owning a major metropolitan newspaper is the ultimate tool for elite status protection and resource optimization.
\nA billionaire does not absorb millions of dollars in annual newsroom losses because he has a deep, spiritual misunderstanding about the civic value of local reporting. He does it because owning the primary narrative engine of a massive media market buys an unmatchable level of social capital, political leverage, and institutional defense. By framing his ownership as a noble, public-spirited sacrifice to “speak on behalf of all Americans,” Soon-Shiong turns a high-cost business venture into a premier moral signal. It ensures that no matter how intense his corporate or regulatory battles become, his name remains attached to the defense of truth and democracy.
\nSoon-Shiong balances his roles by appearing across diverse media spaces\u2014from hosting panels on women’s cancer research for LA Times Studios to discussing industrial robotics at global tech conferences. These platforms are consistently presented as spaces for shared global progress, where leaders gather to solve humanity’s existential dilemmas through innovation and dialogue.
\nPinsof might say that high-status forums are alliance-building engines designed for elite sorting. Human primates do not network at premium tech summits because they want to share ideas for the sheer love of humanity; they do it to pool capital, validate their authority, and secure their market positions.
\nBy using his own newspaper\u2019s studio branch to produce content featuring himself as the visionary expert, Soon-Shiong runs a flawless, self-contained loop of prestige acquisition. He creates the text, manages the platform that broadcasts the text, and reaps the status of the authority who interprets it. He did not buy into media and medicine to change the underlying Darwinian competition of the world; he used them to build an impregnable fortress at the very top of the cultural and financial hierarchy.<\/p>\n","protected":false},"excerpt":{"rendered":"

Patrick Soon-Shiong (b. 1952) is a surgeon, medical inventor, biotechnology executive, investor, philanthropist, and newspaper proprietor whose career joins academic medicine to pharmaceutical commerce on a scale few physicians have matched. He built a large private fortunes through the development … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[76,29729],"tags":[],"class_list":["post-195851","post","type-post","status-publish","format-standard","hentry","category-los-angeles-times","category-medicine"],"_links":{"self":[{"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=\/wp\/v2\/posts\/195851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=195851"}],"version-history":[{"count":11,"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=\/wp\/v2\/posts\/195851\/revisions"}],"predecessor-version":[{"id":195909,"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=\/wp\/v2\/posts\/195851\/revisions\/195909"}],"wp:attachment":[{"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=195851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=195851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lukeford.net\/blog\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=195851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}